<DOC>
	<DOCNO>NCT02075008</DOCNO>
	<brief_summary>This study assess long-term safety QGE031 12 month treatment asthma patient complete study CQGE031B2201 .</brief_summary>
	<brief_title>Long-term Safety Study QGE031 Patients With Allergic Asthma Who Completed Study CQGE031B2201</brief_title>
	<detailed_description>This study assess long-term safety tolerability QGE031 administer every 4 week additional 12 month patient allergic asthma previously complete study CQGE031B2201 .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Key force Expiratory Volume one second ( FEV1 ) &gt; 40 % predict patient complete CQGE031B2201 study Key lifethreatening asthma attack , intubation , respiratory arrest completion CQGE031B2201 study new malignancy ongoing SAE CQGE031B2201 assess related study drug patient experience platelet drop &lt; 75,000/uL patient experience one unexpected grade 4 two unexpected grade 3 hypersensitivity reaction patient pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>allergic asthma</keyword>
	<keyword>QGE031</keyword>
	<keyword>open-label</keyword>
	<keyword>IgE</keyword>
	<keyword>long-term safety</keyword>
</DOC>